DMAA - NASDAQ

Drugs Made In America Acquisition Corp. Ordinary Shares

DMAA·NASDAQ

$10.61

+0.094%

Financial ServicesShell Companies

Drugs Made In America Acquisition Corp. operates as a blank check company. The Company aims to acquire one and more businesses and assets, via a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$357.74M

EPS0.1900

P/E Ratio55.84

Earnings Date—

-539.19K

Operating Cash Flow

213%

3Y+213.0%

5Y+213.0%

10Y+213.0%

-231.15M

Investing Cash Flow

3Y-

5Y-

10Y-

231.69M

Financing Cash Flow

133352%

3Y+133352.0%

5Y+133352.0%

10Y+133352.0%

Drugs Made In America Acquisition Corp. Ordinary Shares Cash Conversion Engine

DMAA · NASDAQ

FCF Components

Net Income3.97M

Depreciation & Amortization0.00

Stock-Based Compensation0.00

Change in Working Capital138.85K

Others-4.65M

Capital Expenditures0.00

Free Cash Flow-539.19K

Cash Flow Quality Analysis

FCF Conversion Rate

-13.6%

Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.

FCF Growth Trend

-182675.3%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

+$138.85K

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Cash Flow Quality Insight

Cash flow concerns: Despite profitability, the company is burning cash. Review working capital management, CapEx levels, and sustainability of current operations.

Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow Statement

DMAA • NASDAQ

Drugs Made In America Acquisition Corp. Ordinary Shares Cash Flow Statement	Dec 2025	Dec 2024
OPERATING ACTIVITIES
Net Income	4M	-479.0
Other Non-Cash Items	-4.6M	-171.9K
Change in Working Capital	138.9K	132.0
Cash from Operating Activities	-539.2K	-172.3K
INVESTING ACTIVITIES
Other Investing Items	-231.2M	0.0
Cash from Investing Activities	-231.2M	(0.0)
FINANCING ACTIVITIES
Net Issuance of Common Stock	232.1M	-328.6K
Net Issuance of Debt	-900K	502.2K
Other Financing Items	544K	0.0
Cash from Financing Activities	231.7M	173.6K
CASH FLOW SUMMARY
Net Change in Cash	4.8K	1.4K
Cash at Beginning of Period	1.4K	0.0
Cash at End of Period	6.1K	1.4K
Free Cash Flow	-539.2K	-295.0

SEC Filings

DMAA - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 05, 2026	April 29, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 01, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 28, 2026	April 22, 2026	2026	View Filing
10-K 10-K 2025 FY FY	April 15, 2026	December 31, 2025	2025	View Filing
DEF 14A DEF 14A 2026 N/A	April 14, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 08, 2026	April 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 27, 2026	March 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	February 28, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 06, 2026	2026	View Filing

Showing 1 to 10 of 26 filings

Related Guides

Blog Categories

Continue your DMAA research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.